Predicting Osteoporosis in Elderly Cancer Patients Using the Modified Glasgow Prognostic Index

Area of Science:

• Oncology
• Geriatrics
• Metabolic Bone Disease

Background:

• Osteoporosis is a significant risk factor for fractures and mortality, particularly in elderly cancer patients.
• Cancer treatments can exacerbate bone loss, increasing the complexity of managing osteoporosis in this population.
• The modified Glasgow Prognostic Score (mGPS), an inflammatory-nutritional marker, is commonly used in oncology but its predictive role for osteoporosis is not well-established.

Purpose of the Study:

• To investigate the association between the modified Glasgow Prognostic Score (mGPS) and bone mineral density in elderly cancer patients.
• To identify predictors of osteoporosis in cancer patients undergoing chemotherapy.
• To evaluate the utility of mGPS as a screening tool for osteoporosis in this vulnerable patient group.

Main Methods:

• A retrospective cross-sectional study involving 93 cancer patients aged 50 years and older.
• Dual-energy X-ray absorptiometry (DXA) scans were used to assess bone mineral density (T-scores).
• Patients were categorized by osteoporosis status (normal, osteopenia, osteoporosis) and mGPS levels; regression analysis was performed.

Main Results:

• Osteoporosis was prevalent in the lumbar spine (41.9%) and osteopenia in the femoral neck (49.5%).
• Higher mGPS scores were significantly associated with lower bone density in the lumbar spine and total femur (P < .001).
• Patients with an mGPS score of 2 had a significantly higher likelihood of osteoporosis (OR = 6.25 for lumbar spine, OR = 5.472 for total femur).

Conclusions:

• The modified Glasgow Prognostic Score (mGPS) is a reliable and cost-effective tool for predicting osteoporosis in elderly cancer patients.
• Integrating mGPS into routine assessments can facilitate early detection and intervention for osteoporosis.
• Utilizing mGPS may improve patient outcomes by proactively addressing bone health in cancer survivors.